Abstract: Methods and reagents are disclosed for detecting a false result in an assay measurement for determining a concentration of an analyte in a sample suspected of containing the analyte. The method comprises measuring assay signal resulting from background only and measuring assay signal resulting from the presence of analyte in the sample plus background and subtracting the first measurement from the second measurement to determine the concentration of analyte in the sample. For example, a measurement result 1 is determined by means of an assay conducted on a portion of the sample where analyte in the sample is substantially sequestered and a measurement result 2 is determined by means of the assay conducted on an equal portion of the same sample where analyte in the sample is substantially non-sequestered. Measurement result 1 is subtracted from measurement result 2 to determine the concentration of analyte in the sample.

Abstract: The present invention relates to systems and methods for minimizing or eliminating diffusion effects. Diffused regions of a segmented flow of multiple, miscible fluid species may be vented off to a waste channel, and non-diffused regions of fluid may be preferentially pulled off the channel that contains the segmented flow. Multiple fluid samples that are not contaminated via diffusion may be collected for analysis and measurement in a single channel. The systems and methods for minimizing or eliminating diffusion effects may be used to minimize or eliminate diffusion effects in a microfluidic system for monitoring the amplification of DNA molecules and the dissociation behavior of the DNA molecules.

Abstract: The present invention is directed to a monoclonal antibody that recognizes human ING4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing cancer using the antibody.

Abstract: A method for diagnosing an increased risk for developing adolescent idiopathic scoliosis (AIS) in a human subject, comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in a cell sample of the subject in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and wherein the presence of the at least one impairment in the melatonin-signaling pathway indicates that the subject possesses an increased risk for developing AIS.

Abstract: Apparatus for immunoassay includes: a cartridge, including at least one test unit; a pin-film assembly, having a second sealing film, a plurality of pierce mechanisms, and a first actuation unit; a plurality of magnetic particles; at least one first magnetic unit; and at least one second magnetic unit. The test unit includes a plurality of fluid chambers, a plurality of pin chambers, a microchannel structure, a buffer chamber, a detection chamber and a waste chamber. The first actuation unit drives the pierce mechanisms to enable a working fluid to flow into the detection chamber storing the magnetic particles. As the second magnetic unit has a magnetic force larger than that of the first magnetic unit and can move reciprocatingly between a third position and a fourth position, the magnetic particles are driven to move reciprocatingly inside the detection chamber, thereby fully mixing the magnetic particles with the working fluid.

Abstract: The methods and kits described herein are based, in part, to the discovery phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent.

Abstract: The invention relates to an ADP binding molecule comprising a polypeptide, said polypeptide comprising amino acid sequence corresponding to at least amino acids 11 to 310 of SEQ ID NO:1, wherein said polypeptide comprises a substitution relative to SEQ ID NO:1 at amino acid C287, and wherein said polypeptide comprises a further cysteine residue for attachment of at least one reporter moiety, and wherein said polypeptide has at least 68% sequence identity to SEQ ID NO:1 at the amino acid residues corresponding to those shown in column III of table A.

Abstract: Provided are peptide analogues of PA-IL and compositions containing them. The PA-IL peptide analogues have altered carbohydrate binding specificity relative to a PA-IL of SEQ ID NO:1, and thus the analogues contain amino acid substitutions in SEQ ID NO:1. The substitutions can be at positions 50, 52 and 53 of SEQ ID NO:1 and can include combinations of amino acid substitutions at those positions Also included are methods for detecting changes in the glycosylation of carbohydrates and for separating biomolecules which contain glycoproteins or glycoconjugates.

Abstract: Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays.

Abstract: The present invention relates to a method for target protein normalization, especially for Western blotting applications. More closely, the invention relates to a method for normalizing target protein signals, after electrophoresis and Western blotting, against variations of sample load or cell number between different lanes or within the same lane on an electrophoretic gel. The signals are normalized against the total protein signal (=ratio between target protein/total protein) or reference protein band signal(s) (=ratio between target protein/reference protein band). According to the invention multiplex and quantitative assessments are possible, such as quantitative comparison between target proteins in different samples.

Abstract: A method and device for periodically perturbing the flow field within a microfluidic device to provide regular droplet formation at high speed.

Abstract: The invention provides a target and methods for specific binding and inhibition of RNAP from bacterial species. The invention is directed to a method for identifying agents that bind to a bacterial RNAP homologous RNA-exit-channel amino-acid sequence, comprising preparing a reaction solution comprising the agent to be tested and an entity comprising a bacterial RNAP homologous RNA-exit-channel amino-acid sequence, and detecting presence or amount of binding. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.

Abstract: The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

Abstract: Human EEF2K genes are identified as modulators of the PTEN/AKT pathway and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT comprising screening for agents that modulate the activity of EEF2K are provided.

Abstract: The present invention relates to methods for measuring an amount of an analyte using an electrochemical assay in a conduit comprising a sensor, wherein said sensor comprises an electrode having a surface layer of immobilized antibody that binds said analyte, and a counter/reference electrode disposed within said conduit. A solution comprising a substrate for said enzyme and at least one air segment contacts the sensor to remove unbound analyte and labeled antibody from a region of the sensor. The disclosed invention is adaptable to the point-of-care clinical diagnostic field, including use in accident sites, emergency rooms, surgery, nursing homes, intensive care units, and non-medical environments.

Abstract: The invention provides a highly sensitive immunoassay for detection of a biological species. The immunoassay comprises exposing an electrode to an analyte liquid putatively containing the biological species so as to couple the biological species, if present in the analyte liquid, to a binding antibody on the electrode. The electrode comprises a binding antibody and an anchor group, each being coupled to an electrically conductive substrate, said binding antibody being capable of binding to the biological species and said anchor group being capable of binding to a redox polymer.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention concerns monomeric or polymeric linker molecules useful in biological and chemical applications, their synthesis, and the synthesis and use of derivatives of the linkers conjugated to a variety of detectable labels and other substances. The linkers may be used, for example, in conjunction with fluorescent labels, nucleic acid or nucleic acid analog probes, and solid phase systems, and to enhance the solubility of the conjugated molecules.

Abstract: The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify metastatic breast cancer patients who are likely to respond to therapy with a VEGF inhibitor. The present invention allows a treatment provider to identify those patients who are most likely to respond to such treatment, and to initiate and/or adjust treatment options for such patients accordingly.

Abstract: The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.

Abstract: This invention relates to methods of distinguishing among various types of differentiated and undifferentiated epithelial carcinomas, and non-epithelial carcinomas, by detecting the presence of p63 nucleic acid or protein expression. The invention also provides methods for detecting p63 nucleic acids and proteins, as well as methods for diagnosing and treating certain tumors based on whether the tumors express p63.

Abstract: The present invention provides a composition for modulating invasion ability of a tumor, comprising: an effective amount of an activator for a miRNA-mediated pathway or an effective amount of a modulating member in the miRNA-mediated pathway being a modulating member, and wherein the miRNA-mediated pathway is regulated by at least one miRNA selected from the group consisting of miR-346, miR-504 and miR-1179. The composition functions according to a novel model that an activator or a modulating member can regulate cellular invasion/migration of tumor via a miRNA-mediated pathway, and thereby can be a potential candidate of molecular drug to treat the tumor by modulating its invasion ability. A method for treating or preventing tumor invasion method is provided as well. Meanwhile, a method for detecting the invasive ability of a tumor in a subject and the kit thereof are also provided.

Abstract: Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.

Abstract: The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.

Abstract: ZSCAN4, a gene expressed in ES cells and 2-cell stage embryos, has been previously shown to regulate telomere elongation and genome stability in mouse ES cells. It is disclosed herein that in the adult human pancreas, a small number of ZSCAN4-positive cells are present among cells located in the islets of Langerhans, acini, and ducts. These data disclosed herein indicates that expression of ZSCAN4 is a marker for rare stem/progenitor cells in adult human pancreas. Thus, provided herein is a method of isolating pancreatic stem cells or progenitor cell from a sample by detecting expression of ZSCAN4. Also provided is a method of treating diabetes by isolating ZSCAN4+ pancreatic stem cells or progenitor cells, expanding the cells in vitro and transplanted the expanded cells into the subject. The expanded ZSCAN4+ cells can optionally be differentiated into pancreatic ? cells before transplanting the cells into the subject.

Abstract: The present invention pertains to the field of tools for ensuring manufacture of polypeptides and quality control. Specifically, it relates to a method for determining the amount of processed (active) neurotoxin polypeptides in a solution comprising processed neurotoxin polypeptides and partially processed or unprocessed neurotoxin polypeptides. The present invention further relates to a device for determining the amount of neurotoxin polypeptides and a kit adapted to carry out the method of the present invention.

Abstract: A method for assaying target molecules in a sample liquid, the method comprising: providing an impedance monitoring device operably connected to an impedance analyzer; adding a sample liquid suspected of having target molecules to the well thereby permitting binding of target molecules to the capture molecules; monitoring impedance of the well; and determining the presence, amount or concentration of target molecules in the liquid sample from the monitored impedance. The device includes a nonconducting substrate having a well, at least two electrodes fabricated on a bottom of the well and on a same plane, wherein the surfaces of the at least two electrodes are modified with capture molecules configured to bind target molecules in a liquid sample, and at least two connection pads electrically connected to the at least two electrodes.

Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease.

Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.

Abstract: The present invention provides a streptavidin-coupled magnetic particle with high biotin-binding capacity, and a manufacturing method thereof. The streptavidin-coupled magnetic particle has a structure in which streptavidins are cross-linked with each other on a magnetic particle. A method for manufacturing the streptavidin-coupled magnetic particle includes the steps of: (1) preparing a suspension containing magnetic particles having amino groups on their surface; and (2) reacting the magnetic particles with streptavidin and glutaraldehyde by adding glutaraldehyde in the presence of streptavidin to the suspension prepared in step (1). The streptavidin-coupled magnetic particle of the present invention, and the streptavidin-coupled magnetic particle manufactured by the manufacturing method of the present invention are useful in clinical diagnosis.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: The present invention relates to a biomarker for the detection of brain damage or a disease associated with loss of neurons, said biomarker comprising a protein fragment of the neurofilament heavy chain (NfH) protein in a biological sample, wherein said protein fragment is a polypeptide selected from the group consisting of i) a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and polypeptides composed of amino acids 476-1026 and 476-986 of SEQ ID NO 6; ii) a protein fragment of the NfH protein having an amino acid sequence that is at least 60% identical to SEQ ID NO:1, at least 60% identical to SEQ ID NO:2, at least 60% identical to SEQ ID NO:3, at least 60% identical to SEQ ID NO:4, at least 60% identical to SEQ ID NO:5; or at least 60% identical to a polypeptide composed of amino acids 476-1026 and.

Abstract: The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. Furthermore, the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy.

Abstract: Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.

Abstract: The present invention relates to a novel molecular marker for pancreatic cancer stem cells and pancreatic cancer, to a marker detection method, and to a screening method. The present invention is a marker discovered from the cell lines of pancreatic cancer, wherein the marker may detect pancreatic cancer, in particular early pancreatic cancer, through the detection of a pancreatic cancer stem cell marker. In addition, the marker of the present invention may enable an accurate diagnosis and prognosis analysis of pancreatic cancer.

Abstract: The present invention relates to a cascade enzyme-linked immunosorbent assay, more precisely a cascade enzyme-linked immunosorbent assay using magnetic microparticles (MMPs) immobilized with the target antigen specific primary antibody and silica nanoparticles (SPs) immobilized with a cascade reaction initiator and the antigen-specific secondary antibody. When the method of the present invention is applied in the detection of an antigen in biosamples, the detection sensitivity can be significantly increased.

Abstract: The present invention relates to methods for diagnosing and treating iron overload and iron deficiency.

Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a veterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. pseudomallei-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. pseudomallei-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. pseudomallei, such as meliodosis.

Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.

Abstract: The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient.

Abstract: This invention refers to a new method for optimizing the composition of cell culture media. This new method comprises two main stages. In the first stage, a functional enviromics map is built through the joint screening of cell functions and medium factors by the execution of a specific cell culture protocol and exometabolome assays protocol. The functional enviromics map consists of a data array of intensity values of elementary cellular functions against medium factors. In the second stage, optimized cell culture medium formulations are developed that either enhance or repress target elementary cellular functions from columns of the functional enviromics map.

Abstract: A test device includes a microfluidic device to conduct a test for biomolecules and controlled to prevent errors in the test, and a control method thereof includes mounting a microfluidic device on a tray, positioning a rotary drive unit at a center of the microfluidic device, and moving the rotary drive unit up and down at least once such that the microfluidic device is seated on the rotary drive unit.

Abstract: The present invention relates to novel lateral flow devices using DNA dendrimers, and the methods for detecting an analyte using the lateral flow devices.

Abstract: Three-dimensional microfluidic devices including by a plurality of patterned porous, hydrophilic layers and a fluid-impermeable layer disposed between every two adjacent patterned porous, hydrophilic layers are described. Each patterned porous, hydrophilic layer has a fluid-impermeable barrier which substantially permeates the thickness of the porous, hydrophilic layer and defines boundaries of one or more hydrophilic regions within the patterned porous, hydrophilic layer. The fluid-impermeable layer has openings which are aligned with at least part of the hydrophilic region within at least one adjacent patterned porous, hydrophilic layer. Microfluidic assay device, microfluidic mixer, microfluidic flow control device are also described.

Abstract: The present invention relates to a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA1 SLIK and/or SALSA complexes in said cell.

Abstract: The invention provides methods relating to the diagnosis and treatment of diastolic heart failure, kits for diagnosing diastolic heart failure or diastolic dysfunction, and related systems, computer readable storage media, and methods implemented by a processor in a computer.

Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

Abstract: The invention provides a method of diagnosis of a spongiform encephalopathy in a diagnostic sample of a valid body tissue taken from a subject, which comprises detecting an increased proteolytic activity in the diagnostic sample, compared with a sample from a control subject.